Joe Anderson, chief executive of Arix Bioscience Plc (LON:ARIX), tells Proactive Investors they posted strong first half numbers as two of their portfolio companies listed on Nasdaq.
Net asset value over the half year to June jumped by 76% to £257.6mln, with its portfolio of thirteen stakes in biotech companies rising in value by £35.6mln.
Strategic agreements were signed with Fosun International and Ipsen, in addition to the existing relationships with Takeda and UCB Pharma, while a collaboration deal was agreed with Fred Hutchinson Cancer and Evotec